News

Clinical Trials Arena4h
Adicet Bio doses first SSc subject in second cohort of trial evaluating ADI-001
Adicet Bio has dosed the first systemic sclerosis (SSc) subject in the Phase I trial’s second cohort evaluating ADI-001.
Clinical Trials Arena6h
First subject dosed in Phase I trial of Vir Biotechnology’s VIR-5525
Vir Biotechnology has dosed the first subject in the non-randomised Phase I trial to assess VIR-5525, the investigational dual-masked TCE.
Clinical Trials Arena22h
gMG race hots up as AstraZeneca’s star candidate meets Phase III targets
Gefurulimab met all primary and secondary endpoints in the Phase III PREVAIL trial in patients with gMG, run by pharma giant AstraZeneca.